Odyssey Therapeutics is a clinical-stage biopharmaceutical company developing oral small-molecule and protein-based drugs for inflammatory and autoimmune diseases. Founded in 2021, Odyssey has no approved products or commercial revenue. The company's core thesis is that existing treatments for inflammatory diseases target the adaptive immune system too far downstream — blocking individual cytokines like TNF or IL-23 — while Odyssey targets the innate immune system upstream, aiming to block multiple inflammatory pathways simultaneously and address the root cause of disease. Odyssey's lead program, OD-001, is an oral RIPK2 scaffolding inhibitor in Phase 2a for ulcerative colitis, where it recently achieved proof-of-concept with 27% clinical remission and 61% clinical response among evaluable patients. Its second program, OD-002, is an oral SLC15A4 inhibitor targeting the TLR7/8/9 signaling pathway implicated in lupus and other interferon-driven diseases, currently in IND-enabling studies. Earlier-stage programs include OD-003, a TNFR2 agonist designed to expand regulatory T cells, OD-004, a bispecific blocking TSLP and IL-33 for respiratory diseases, an IRAK4 scaffolding inhibitor, and an IRF5 inhibitor co-developed with Terray. Odyssey funds operations through equity financing and has raised ~$726.5M in preferred stock since inception. The company's strategy combines advancing its pipeline toward pivotal readouts with selective partnerships, and management has a track record of program and company exits at substantial premiums.